ARRY
Array Technologies, Inc.
19.35
0.96(+5.22%)<--------------- starting to move from $17 entry)))))
12:20 PM 10/11/21
Array Technologies, Inc.
19.35
0.96(+5.22%)<--------------- starting to move from $17 entry)))))
12:20 PM 10/11/21
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA Presents: THE GREEN MARKET
- Thread starter stonedinvestor
- Start date
You know what friggin' IWM is lol.Nice job Van! I heard something about them fudging numbers to beat these earnings (probably will) but business being weak...
What's IWM?
Hey I have a volume alert on EVLO, now don't confuse it with that pos spac evlv... it's a bio, and I'm not seeing any news.
Wanna check it out?
Evelo Biosciences.
$7.57
Ocular Therapeutix rises as FDA posting indicates approval of new indication 11:00 OCUL
Kore Group initiated with an Outperform at Cowen 10:26 KORE Cowen analyst Lance Vitanza initiated coverage of Kore Group (KORE) with an Outperform rating and $18 price target. The company has 3,600 customers, mostly large global enterprises like Abbott Labs (ABT), and Vitanza sees limited fundamental downside risk given its robust, proprietary connectivity network, which is differentiated and would at best take years to replicate, and thinks it delivers a steady stream of revenue at +60% gross margin, the analyst tells investors in a research note.??
Who is Kore?
Not these guys)
DIVERSITY CHECK- FAIL
Van how bout me calling out Arrival like that! And it takes off-- that The Savant in high form!
Lets see a robot do this! I bet they can... but I wonder
Kore Group initiated with an Outperform at Cowen 10:26 KORE Cowen analyst Lance Vitanza initiated coverage of Kore Group (KORE) with an Outperform rating and $18 price target. The company has 3,600 customers, mostly large global enterprises like Abbott Labs (ABT), and Vitanza sees limited fundamental downside risk given its robust, proprietary connectivity network, which is differentiated and would at best take years to replicate, and thinks it delivers a steady stream of revenue at +60% gross margin, the analyst tells investors in a research note.??
Who is Kore?
Not these guys)
DIVERSITY CHECK- FAIL
Van how bout me calling out Arrival like that! And it takes off-- that The Savant in high form!
Lets see a robot do this! I bet they can... but I wonder
WHO LOVES YA!
Dutch Bros Inc. (BROS)
NYSE - Nasdaq Real Time Price. Currency in USD
48.33+5.67 (+13.31%)
As of 12:45PM EDT.
Dutch Bros Inc. (BROS)
NYSE - Nasdaq Real Time Price. Currency in USD
48.33+5.67 (+13.31%)
As of 12:45PM EDT.
EVLO SHELF OFFERING? 8/23 Evelo Biosciences files $200M mixed securities shelf
You know what friggin' IWM is lol.
It's not Iron Mountain
Damn! Got to be faster...
OCUL
Ocular Therapeutix
$11.28
+1.52(+15.57%)
OCUL
Ocular Therapeutix
$11.28
+1.52(+15.57%)
Ocular Therapeutix rises as FDA posting indicates approval of new indication 11:00 OCUL
I decided to give OCUL a look and it caught my eye (no pun intended). that is some serious growth even before the new FDA approval. i'll open a small position today. thanks for the tip!
GET READY!
Ocular Therapeutix, Inc. (OCUL)- $1 off HIGH!!
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.14+1.39 (+14.28%)
As of 12:54PM EDT.
1>
Ocular Therapeutix announces FDA approval of Dextenza sNDA 12:31 OCUL Ocular Therapeutix announced the U.S. FDA has approved its Supplemental New Drug Application to broaden the DEXTENZA label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the approval, DEXTENZA is the first, FDA-approved, physician-administered intracanalicular insert capable of delivering a preservative-free drug for the treatment of ocular itching associated with allergic conjunctivitis with a single administration for up to 30 days, Ocular said in a statement. DEXTENZA originally received FDA approval in November 2018 for the treatment of ocular pain following ophthalmic surgery, followed by an expansion of the label to also include the treatment of ocular inflammation following ophthalmic surgery in June 2019, it added. The efficacy of DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis was based on three randomized, multicenter, double-masked, parallel group, vehicle-controlled studies in subjects with a positive history of ocular allergies and positive skin test reaction to perennial and seasonal allergens. In all three trials, DEXTENZA demonstrated lower mean ocular itching scores compared with the vehicle group at all time points throughout the study duration of up to 30 days.
2>
Ocular Therapeutix reports in-market unit sales of DEXTENZA billable inserts 09/13 OCUL Ocular Therapeutix reported in-market unit sales of DEXTENZA billable inserts of 6,924 and 9,321 in July and August, respectively, as part of the company's corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference. August units represent the second highest month of in-market unit sales of DEXTENZA billable inserts to date.
3>
Ocular Therapeutix CEO buys 5K shares of common stock 08/24 OCUL In a regulatory filing, Ocular Therapeutix disclosed that its CEO Antony Mattessich bought 5K shares of common stock on August 20th in a total transaction size of $49.5K, boosting his stake by about 5%. Shares of Ocular Therapeutix are up 1.9% in pre-market trading at $10.60.
4>
Ocular Therapeutix upgraded to Buy from Neutral at H.C. Wainwright 08/10 OCUL H.C. Wainwright analyst Yi Chen upgraded Ocular Therapeutix to Buy from Neutral with a $17 price target after the company reported "strong" Dextenza sales growth in Q2 and management said it expects to see strong growth through the remainder of the year due to continued physician interest in the drug as well as more normalized cataract procedure volumes. Dextenza could obtain FDA approval of its supplemental New Drug Application for the treatment of ocular itching associated with allergic conjunctivitis on the PDUFA date of October 18, driving further market adoption, noted Chen.
Ocular Therapeutix reports preliminary Q2 product revenue of $11.7M 07/22 OCUL The Company is reporting preliminary second quarter 2021 total net product revenue of approximately $11.7 million, representing a greater than 600% year-over-year increase versus the second quarter 2020 and an approximately 60% sequential increase over the first quarter of 2021. President and CEO. "What gives us the greatest satisfaction however is knowing that more and more patients are enjoying a better experience following their ophthalmic surgeries."
Insider was $10.40 it looks like VAN THIS IS A BUY!
Ocular Therapeutix, Inc. (OCUL)- $1 off HIGH!!
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.14+1.39 (+14.28%)
As of 12:54PM EDT.
1>
Ocular Therapeutix announces FDA approval of Dextenza sNDA 12:31 OCUL Ocular Therapeutix announced the U.S. FDA has approved its Supplemental New Drug Application to broaden the DEXTENZA label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the approval, DEXTENZA is the first, FDA-approved, physician-administered intracanalicular insert capable of delivering a preservative-free drug for the treatment of ocular itching associated with allergic conjunctivitis with a single administration for up to 30 days, Ocular said in a statement. DEXTENZA originally received FDA approval in November 2018 for the treatment of ocular pain following ophthalmic surgery, followed by an expansion of the label to also include the treatment of ocular inflammation following ophthalmic surgery in June 2019, it added. The efficacy of DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis was based on three randomized, multicenter, double-masked, parallel group, vehicle-controlled studies in subjects with a positive history of ocular allergies and positive skin test reaction to perennial and seasonal allergens. In all three trials, DEXTENZA demonstrated lower mean ocular itching scores compared with the vehicle group at all time points throughout the study duration of up to 30 days.
2>
Ocular Therapeutix reports in-market unit sales of DEXTENZA billable inserts 09/13 OCUL Ocular Therapeutix reported in-market unit sales of DEXTENZA billable inserts of 6,924 and 9,321 in July and August, respectively, as part of the company's corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference. August units represent the second highest month of in-market unit sales of DEXTENZA billable inserts to date.
3>
Ocular Therapeutix CEO buys 5K shares of common stock 08/24 OCUL In a regulatory filing, Ocular Therapeutix disclosed that its CEO Antony Mattessich bought 5K shares of common stock on August 20th in a total transaction size of $49.5K, boosting his stake by about 5%. Shares of Ocular Therapeutix are up 1.9% in pre-market trading at $10.60.
4>
Ocular Therapeutix upgraded to Buy from Neutral at H.C. Wainwright 08/10 OCUL H.C. Wainwright analyst Yi Chen upgraded Ocular Therapeutix to Buy from Neutral with a $17 price target after the company reported "strong" Dextenza sales growth in Q2 and management said it expects to see strong growth through the remainder of the year due to continued physician interest in the drug as well as more normalized cataract procedure volumes. Dextenza could obtain FDA approval of its supplemental New Drug Application for the treatment of ocular itching associated with allergic conjunctivitis on the PDUFA date of October 18, driving further market adoption, noted Chen.
Ocular Therapeutix reports preliminary Q2 product revenue of $11.7M 07/22 OCUL The Company is reporting preliminary second quarter 2021 total net product revenue of approximately $11.7 million, representing a greater than 600% year-over-year increase versus the second quarter 2020 and an approximately 60% sequential increase over the first quarter of 2021. President and CEO. "What gives us the greatest satisfaction however is knowing that more and more patients are enjoying a better experience following their ophthalmic surgeries."
Insider was $10.40 it looks like VAN THIS IS A BUY!
WATCH THESE GUYS GET BOUGHT OUT TOMORROW GUARANTEED!!!->GIVING UP ON TURTLE BEACH VAN -- SELLING ABSOLUTELY FLAT A LOT OF TIME WASTED... I'M RAISING CASH FOR THIS EYE COMPANY!!!! UNCONVENTIONAL IS SELDOM WRONG!